Canadian biotech firm Tekmira Pharmaceuticals (TKMR)announced that the
Federal Drug Administration knocked down a key barrier to its
medicine, TKM Ebola, reaching some patients. The FDA moved the drug
from a "full hold" to a "partial hold," which means Tekmira can use
the drug in limited experiments.
"We are pleased that the FDA has considered the risk-reward of
TKM-Ebola for infected patients," said CEO Mark Murray in a statement.
"We have been closely watching the Ebola virus outbreak and its
consequences, and we are willing to assist with any responsible use of
TKM-Ebola."
Investors have been keen to find a way to put money into an Ebola
cure. Shares jumped as much as 40% in recent days as news of Tekmira's
drug became widely known. But the stock fell back after officials at
the Emory University hospital treating two Ebola patients used another
company's drugs.
Investors think the drug could still become a big moneymaker for
Tekmira, and the FDA upgrade in status is being viewed as added
confirmation of the potential for the treatment.
Jason Kolbert, an analyst with the Maxim Group, told CNNMoney earlier
this week that Ebola's sudden and rapid spread moved federal officials
to try out a number of Ebola treatments in development, so Tekmira
still has a shot at a payday.
No comments:
Post a Comment